Back to Newsroom
Back to Newsroom

Immune Therapeutics to Present at the 7th Annual LD Micro Invitational

Monday, 05 June 2017 08:45 AM

Immune Therapeutics, Inc.

LOS ANGELES, CA / ACCESSWIRE / June 5, 2017 / Immune Therapeutics, Inc. (OTCQB: IMUN), a specialty pharmaceutical company focused on developing and commercializing our novel patented, affordable, non-toxic therapy for the management of cancer, HIV, autoimmune diseases, and other inflammatory conditions, today announced that it will be presenting at the 7th annual LD Micro Invitational on Wednesday, June 7 at 9:00 AM PST / 12:00 PM EST. Chief Executive Officer, Noreen Griffin, will be giving the presentation and meeting with investors.

Immune Therapeutics recently announced that it has received NAFDAC (National Agency for Food and Drug Administration and Control) approval to market and distribute LodonalTM, the Company's breakthrough treatment for HIV/AIDS in Nigeria. The Company and its strategic partners plan to immediately initiate sales activities of this first-to-market opportunity.

"With Immune Therapeutics' recently announced debt restructuring, the company is well positioned to move forward with its business plan, which calls for a significant ramp-up in revenues and achievement of profitability by the end of the fourth quarter," stated Ms. Griffin. "In addition to Nigeria, the company expects to obtain regulatory approvals in Kenya, Senegal, and Cote d'Ivoire by the fourth quarter of 2017 or early in 2018. We are very proud of the many achievements this company has made over the past several years and look forward to updating our shareholders on our commercialization strategy followed by the announcement of initial contracts."

"This year, not only do we have a record number of companies making their LD Micro debuts, but a record number of companies presenting for the first time in their company's history," stated Chris Lahiji, President of LD Micro. "LD has established itself as the one venue that brings the most influential players from all segments of the market under one roof."

The conference will be held at the Luxe Sunset Bel Air Hotel and will feature 180 companies in the small / micro-cap space.

View Immune Therapeutics' profile here: https://www.ldmicro.com/profile/IMUN

Profiles powered by LD Micro - News Compliments of ACCESSWIRE.

About Immune Therapeutics, Inc.

Immune Therapeutics, Inc. (OTCQB: IMUN) is a clinical-stage biopharmaceutical company developing its proprietary version of lower-dose naltrexone, Lodonal™, as a standalone and conjunctive therapy in patients with a wide variety of conditions including HIV/AIDS, autoimmune diseases, cancer, neurodegenerative conditions and other inflammatory conditions. Lodonal™ is a novel compound with a unique mechanism of action and has clinical data on over 2,000 patients in several clinical studies. The drug has a favorable safety profile, is well tolerated by patients and has demonstrated efficacy in at least one clinically meaningful endpoint.

About LD Micro

LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space. What started out as a newsletter highlighting unique companies has transformed into an event platform hosting several influential conferences annually (Invitational, Summit, and Main Event).

In 2015, LDM launched the first pure microcap index (the LDMi) to exclusively provide intraday information on the entire sector. LD will continue to provide valuable tools for the benefit of everyone in the small and microcap universe.

For those interested in attending, please contact David Scher at [email protected] or visit www.ldmicro.com for more information.

Forward-Looking Statements

This release may contain forward-looking statements. Actual results may differ from those projected due to a number of risks and uncertainties, including, but not limited to, the possibility that some or all of the matters and transactions considered by the Company may not proceed as contemplated, and by all other matters specified in the Company's filings with the Securities and Exchange Commission. These statements are made based upon current expectations that are subject to risk and uncertainty. The Company does not undertake to update forward-looking statements in this news release to reflect actual results, changes in assumptions or changes in other factors affecting such forward-looking information. Assumptions and other information that could cause results to differ from those set forth in the forward-looking information can be found in the Company's filings with the Securities and Exchange Commission (www.sec.gov), including its recent periodic reports.

Investor/Media Contact:

Bill Miller
Investor Relations Partners
Phone: 844-565-5665
[email protected]

SOURCE: Immune Therapeutics, Inc.

Topic:
Conferences
Back to newsroom
Back to Newsroom
Share by: